Ocular Therapeutix (OCUL) Misses Q4 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- AMD shares fall amid AI chip sector selloff
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
Ocular Therapeutix (OCUL) PT Lowered to $17 at BofA Securities, PT $17
March 3, 2025 11:48 AM ESTBofA Securities analyst Tazeen Ahmad lowered the price target on Ocular Therapeutix (NASDAQ: OCUL) to $17.00 (from $18.00) while maintaining a Buy rating.
The analyst comments "Ocular (OCUL) reported an amendment to the SPA for SOL-1 to include re-dosing at weeks 52 and 76. Mgmt underscored the 9-month... More



